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ABSTRACT 
Background:  Hypertension  is  a  crucial  risk  factor  for  development  of  cardiovascular  and 
neurological  diseases.  Flavonoids  exhibit  a  wide  range  of  biological  effects  and  have  had 
increased interest as a dietary approach for the prevention or possible treatment of hypertension. 
However, continuous efforts have been made to structurally modify natural flavonoids with the 
hope  of  improving  their  biological  activities.  One  of  the  methods  used  for  the  possible 
enhancement of flavonoid efficacy is enzymatic esterification of flavonoids with fatty acids.  
 
Objective:  The  current  study  is  designed  to  investigate  the  antihypertensive  activity  of 
isoquercitrin (quercetin-3-O-glucoside, Q3G) and phloridzin (PZ) in comparison to their twelve 
long chain fatty acid derivatives via enzymatic inhibition of renin angiotensin aldosterone system 
(RAAS) enzymes.  
 
Methods: The novel flavonoid esters were synthesized by the acylation of isoquercitrin and 
phloridzin  with  long  chain  unsaturated  and  saturated  fatty  acids  (C18–C22).  These  acylated 
products were then tested for their in vitro angiotensin converting enzyme (ACE), renin and 
aldosterone synthase activities. 
 
Results: The linoleic and α-linolenic acid esters of PZ were the strongest (IC50 69.9-70.9 µM) 
while Q3G and PZ (IC50 >200 µM) were the weakest renin inhibitors in vitro (p≤0.05). The 
eicosapentaenoic acid ester of PZ (IC50 16.0 µM) was the strongest inhibitor of ACE, while PZ 
(IC50 124.0 µM) was the weakest inhibitor (p≤0.05) among all tested compounds. However, all 
investigated compounds had low (5.0-11.9%) or no effect on aldosterone synthase inhibition 
(p≤0.05). The parent compound Q3G and the eicosapentaenoic acid ester of PZ emerged as the 
strongest ACE inhibitors. 
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Conclusions:  The  structural  modification  of  Q3G  and  PZ  significantly  improved  their 
antihypertensive activities. The potential use of PZ derivatives as natural health products to treat 
hypertension needs to be further evaluated. 
 
Keywords: hypertension, phloridzin, isoquercitrin, flavonoids, ACE, renin, RAAS, acylation, 
fatty acids 
 
 
INTRODUCTION: 
Hypertension is the most common risk factor for cardiovascular diseases including myocardial 
infarction, stroke and kidney disease. The renin angiotensin aldosterone system (RAAS) is a 
physiological mechanism which regulates the blood pressure through the modulation of renal 
vasomotor function, salt and water balance [1].
 Renin enzyme converts angiotensinogen into 
angiotensin I (Ang I) while Angiotensin Converting Enzyme (ACE) produced by endothelial 
lung  cells  further  hydrolysis  decapeptide  Ang  I  into  octapeptide  angiotensin  II  (Ang  II), 
triggering aldosterone secretion, which maintains normal blood pressure and salt balance under 
normal physiological conditions [1, 2].
 However, the overproduction of the principal biochemical 
components of the RAAS system, including renin, ACE and aldosterone synthase, disturbs the 
RAAS  equilibrium  and  triggers  the  pathophysiology  of  hypertension.  Many  drugs  target 
inhibition  of  these  three  enzymes  of  RAAS  (renin,  ACE  and  aldosterone  synthase)  for 
attenuation of hypertension and other cardiac disorders [3]. In recent years, there has been an 
interest  in  identifying  natural  compounds  and  their  derivatives  for  their  antihypertensive 
properties based on RAAS  inhibition. One particular category of natural compound that has 
received recent attention for their antihypertensive action is the flavonoids [4, 5]. 
Flavonoids are a class of polyphenolic plant secondary metabolites with diverse structures 
and functions [6]. There are over 9,000 characterized flavonoids that exhibit pharmacological 
properties  such  as  antioxidants,  anticarcinogens  and  immunomodulators  [7,  8].  The  vast 
spectrum of in vitro properties of flavonoids is questionedbecause the low bioavailability of 
flavonoids, due to poor absorption and extensive metabolism [9].
 To enhance bioavailability and 
biological  activities  of  flavonoids,  various  techniques,  such  as  microencapsulation  [10]  and 
enzymatic esterification of flavonoids with fatty acids [11], have been employed. In a previous 
study,  12  novel  acylated  derivatives  of  isoquercitrin  and  phloridzin  were  synthesized  and 
examined for selected biological properties [12]. In the current study, both precursor flavonoids 
isoquercitrin and phloridzin along with 12 fatty acid derivatives were studied for their renin, 
ACE and aldosterone synthase inhibitory properties in vitro. 
 
METHODS: 
Materials  
The  ACE,  Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(DABCYL)-Arg 
(renin substrate), dimethyl sulfoxide (DMSO), ethyl acetate, HCl, histidine-leucine (His-Leu), 
histidine-L-hippuryl-L-leucine-chloride (HHL), isoquercitrin, lipase B from Candida antarctica 
(with  an  activity  of  10,000  propyl  laurate  units),  NaOH,    o-pthaldehyde,  phloridzin,  renin 
(human  recombinant)  and  Tris  buffer  were  purchased  from  Sigma  Aldrich  Canada  Ltd., Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 210 of 221 
Oakville, ON, Canada. Kidney tissue lysate was obtained from GeneTex, INC, Irvine, CA, USA. 
[4-
14C]-11-Deoxycorticosterone  was  obtained  from  Phenomenex  Torrance,  CA,  USA. 
Dulbecco's modified eagle medium (DMEM) media and cell culture grade DMSO were obtained 
from  Cederlane  Labs,  Burlington,  ON,  Canada.  Round  bottom  96-well  clear  and  black 
microplates  were  obtained  from  BD  International,  Mississauga,  ON,  Canada  and  Corning 
Incorporated, Edison, NY, USA, respectively. 
 
Synthesis of novel esterified flavonoids: The synthesis of novel esterified flavonoids has been 
carried out as previously described [12]. Briefly, the acylation of isoquercitrin and phloridzin 
was performed at a temperature between 45–50 °C in acetone with lipase B (Novozym 435
®) 
from Candida antarctica with long chain unsaturated and saturated fatty acids (C18–C22). In 
order to achieve high enzyme efficiency, the substrate was dried for a period of 18–20 h over 
P2O5  before  initiating  the  synthesis  reaction.  The  progress  and  products  of  reaction  were 
monitored  and  detected  using  thin-layer  chromatography  (TLC).  The  structures  of  acylated 
flavonoids  were determined by 
1H NMR  and 
13C NMR spectroscopic analysis using Bruker 
AVANCE  300 MHz  spectrometer  (Bruker  Corp.,  Billerica,  MA,  USA).  The  resynthesized 
compounds were stored at -80°C. The compounds were dissolved separately in DMSO to make a 
stock solution of 1 mM, which was then diluted for further analysis. 
 
Renin inhibition assay: The renin inhibitory potential of parent flavonoids and their esterified 
derivatives was determined with accordance to previously described methodology, allowing for 
some modifications [13]. Then, 50 µl of renin was dissolved in the assay buffer consisting of 50 
mM Tris-HCl buffer (pH 8.0) and 100 mM NaCl (assay buffer). The activated enzyme was 
stored at -80°C, awaiting further analysis. Renin substrate (Arg-Glu(EDANS)-Ile-His-Pro-Phe-
His-Leu-Val-Ile-His-Thr-Lys(Dabcyl)-Arg) was diluted with DMSO to achieve a concentration 
of 500 µM. The assay was performed using 96-well black polypropylene plates. The background 
controls contained 20 µl of substrate along with 160 µl of assay buffer and 10 µl of DMSO 
(solvent control). The positive control was comprised of 20 µl of substrate, 150 µl of assay 
buffer and 10 µl of DMSO. The test compounds were analyzed using 20 µl of substrate, 150 µl 
of assay buffer and 10 µl of the test compound at the desired concentrations. The reaction was 
catalyzed by adding 10 µl of renin solution to the positive control and test compounds. The 
reaction mixture was incubated at 37°C for 45 minutes and the fluorescence signal produced 
from the  cleavage of  fluorophore-EDANS to  peptide-EDANS  by renin was  measured at  the 
excitation wavelength of 340 nm and the emission wavelength of 490 nm using the FLUOstar 
OPTIMA  plate  reader  (BMG  Labtech  Inc.,  Offenburg,  Germany).  The  renin  inhibition  was 
expressed at percentage inhibition using the following formula: 
 
 
 
 
ACE inhibition assay: The ACE inhibition potential of two flavonoids along with its esterified 
derivatives was tested according to a previously reported methodology [5]. The analysis was Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 211 of 221 
carried out using test compounds at different concentrations, 2.5 mU ACE, 0.80 mM HHL and 
2.5  mM  sodium  borate  buffer  (pH  8.3).  The  evaluation  of  ACE  inhibitory  potential  of  test 
compounds was dependent on His-Leu formation by the cleavage of HHL in the presence of 
ACE.  This  assay  was  performed  using  96-well  clear  polystyrene  plates  (BD  International, 
Mississauga,  ON,  Canada).  The  formation  of  His-Leu  was  measured  using  the  florescence 
method, using the FLUOstar OPTIMA plate reader (BMG Labtech Inc., Offenburg, Germany) at 
excitation and emission wavelengths of 360 nm and 500 nm, respectively. Calculations were 
performed, as previously outlined [5]. The results were expressed as the percentage inhibition of 
ACE inhibition and the IC50 values were calculated by linear interpolation. 
 
Aldosterone  synthase  inhibition  assay:  The  assay  was  conducted  according  to  the  method 
outlined in a previous study [14], with some modification. This assay is based on the principle 
that  the  potential  aldosterone  inhibitor  can  reduce  the  conversion  rate  of  substrate,  [4-
14C]-
deoxycorticosterone to [4-
14C]-aldosterone. One hundred microliters of human kidney lysate was 
transferred onto a 24-well plate containing 700 µl of DMEM media per well. Test compounds 
were added, at the final test concentrations of 100 µM, along with DMSO for assay control. The 
compounds  were  incubated  for  20  minutes  and  the  assay  substrate  500  nM  [4-
14C]-
deoxycorticosterone was added. The assay mixture was allowed to incubate for 6 h and  the 
steroids were removed using ethyl acetate. The steroid mixture was dried and then re-dissolved 
in 20 µl chloroform and analyzed with respect to a positive control using the FLUOstar OPTIMA 
plate reader (BMG Labtech Inc., Offenburg, Germany) at the wavelength of 490 nm.  
 
Statistical and correlational analysis: Completely randomized design was used to perform the 
experiments, where each compound was assayed in triplicates (n=3). Statistical analysis was 
carried out using SAS 9.3 for Windows (SAS Institute Inc, Cary, NC, USA) and Minitab 16 
(State College PA, USA). One way ANOVA was performed and the resultant values at p≤0.05 
were considered significant. The Pearson coefficient obtained from Minitab 16 (State College 
PA, USA) was used for correlational analysis. 
 
RESULTS:  
Renin inhibition: Renin is an important enzyme in RAAS, as its pathological overproduction 
increases the level of peptide angiotensin I in the blood, leading to higher blood pressure. Natural 
compounds [15] and plant extracts [16] have shown strong renin inhibitory properties. Renin 
inhibition  assay  in  vitro  was  conducted  to  assess  the  renin  inhibitory  properties  of  novel 
flavonoid derivatives (Table 1). For the series of Q3G derivatives, the renin assay resulted in 
significantly stronger renin inhibitory potential for the Q3G derivatives than the parent flavonoid 
(p≤0.05).  
        The IC50 value for Q3G was >200 µM, however the IC50 values for Q3G derivatives ranged 
between 73.03 to 93.09 µM. Among the Q3G derivatives, the oleic acid derivative (IC50 73.0 
µM) showed the strongest renin inhibition, while the eicosapentaenoic acid (EPA) ester of Q3G 
(IC50 93.1 µM) was the weakest renin inhibitor (p≤0.05). Similar to Q3G, all the phloridzin series 
esters showed the higher antihypertensive potential than its parent compound (p≤0.05). Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 212 of 221 
Table 1 Renin inhibition by novel fatty acid esters of isoquercitrin (Q3G) and phloridzin in vitro. 
 
§Data are presented as mean of three replicates. Mean with various subscripts in each column represent levels 
of significance (p≤0.05);  
x Micro molar (μM) 
y Not detected (ND) 
z Inhibitory Concentration 50 percent (IC50)  
∞  Isoquercitrin  (Q3G);  Stearic  acid  ester  of  Q3G  (Q3G-Stearic);  Oleic  acid  ester  of  Q3G  (Q3G-  Oleic); 
Linoleic  acid  ester  of  Q3G  (Q3G-  Linoleic);  α-linolenic  acid  ester  of  Q3G  (Q3G-  α-linolenic); 
Eicosapentaenoic acid ester of Q3G (Q3G-EPA); Phloridzin (PZ); Stearic acid ester of PZ (PZ-Stearic); Oleic 
acid ester of PZ (PZ- Oleic); Linoleic acid ester of PZ (PZ- Linoleic); α-linolenic acid ester of PZ (PZ- α-
Linolenic); Eicosapentaenoic acid ester of PZ (PZ-EPA); Docosahexaenoic acid ester of PZ (PZ-DHA) 
 
Phloridzin exhibited lower renin inhibition (IC50 value > 200 µM) than that of its esters. The 
IC50 values of phloridzin esters ranged between 69.9 to 95.6
 µM. The strongest renin inhibitory 
potential among the compounds was that of linoleic ester of phloridzin with IC50 value of 69.9 
µM (p≤0.05). Linoleic ester of phloridzin was also accompanied by its α-linolenic acid ester 
(IC50 70.9 µM) as the strongest renin inhibitor. However, the EPA ester of phloridzin exhibited 
the weakest renin inhibition in vitro (p≤0.05). The results showed that presence of a longer 
carbon chain with multiple double bonds negatively impacted the renin inhibitory potential of the 
lipophilized flavonoids. However, the short chained α-linolenic acid and linoleic acids when 
attached to a parent flavonoid elevated its antihypertensive abilities. 
 
ACE inhibition: The overproduction of ACE catalyzes uncontrolled conversion of angiotensin I 
to angiotensin II, leading to the constriction of blood vessels through bradykinin degradation 
and,  subsequently,  hypertension.  Polyphenolic  compounds  are  potent  antihypertensive  agents 
[17] with strong ACE inhibitory properties [4, 5]. Many flavonoid-rich extracts and powder have 
Concentration 
(μM)
x 
In vitro Percentage inhibition of Renin
 § 
  Q3G
∞  Q3G-
Stearic 
Q3G-
Oleic 
Q3G-
Linoleic 
Q3G- α 
Linoleic 
Q3G-
EPA 
Q3G-
DHA 
1  N.D
y  N.D  N.D  N.D  N.D  N.D  N.D 
10  17.03
c  37.82
c  51.69
b  46.80
c  47.74
c  29.78
c  48.69
c 
100  25.22
b  52.31
b  53.40
b  61.19
b  63.31
b  49.73
b  59.56
b 
1000  31.19
a  67.59
a  69.14
a  73.93
a  70.40
a  68.64
a  62.28
a 
IC50
z
 (μM)  >200
h  89.34
f  73.03
b  78.69
d  76.37
c  93.09
g  81.49
e 
  PZ  PZ-
Stearic 
PZ-Oleic  PZ-
Linoleic 
PZ -α 
Linoleic 
PZ-EPA  PZ-
DHA 
1  N.D  N.D  N.D  N.D  N.D  N.D  N.D 
10  5.73
c  58.07
c  40.6
c  44.98
c  30.41
c  33.60
c  26.02
c 
100  26.64
b  63.31
b  65.94
b  69.83
b  68.65
b  62.70
b  48.77
b 
1000  40.59
a  66.65
a  73.59
a  90.66
a  80.24
a  94.22
a  82.14
a 
IC50 (μM)  >200
h  76.45
c  72.89
ab  69.94
a  70.86
a  79.19
d  95.61
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also shown to exhibit antihypertensive properties [4, 5, 18]. The present study investigated the 
ACE inhibitory potential of acylated derivatives of phloridzin and Q3G (Table 2).  
 
Table 2 ACE inhibition by novel fatty acid esters of isoquercitrin (Q3G) and phloridzin in vitro. 
 
§Data  are  presented  as  mean  of  three  replicates.  Mean  with  various  subscripts  in  each 
column represent levels of significance (p≤0.05);  
x Micro molar (μM) 
y Not detected (ND) 
z Inhibitory Concentration 50 percent (IC50)  
∞ Isoquercitrin (Q3G); Stearic acid ester of Q3G (Q3G-Stearic); Oleic acid ester of Q3G 
(Q3G- Oleic); Linoleic acid ester of Q3G (Q3G- Linoleic); α-linolenic acid ester of Q3G (Q3G- 
α-linolenic); Eicosapentaenoic acid ester of Q3G (Q3G-EPA); Phloridzin (PZ); Stearic acid ester 
of PZ (PZ-Stearic); Oleic acid ester of PZ (PZ- Oleic); Linoleic acid ester of PZ (PZ- Linoleic); 
α-linolenic acid ester of PZ (PZ- α-Linolenic); Eicosapentaenoic acid ester of PZ (PZ-EPA); 
Docosahexaenoic acid ester of PZ (PZ-DHA) 
 
In contrast to inhibition of renin, the parent flavonoids showed active inhibition of ACE in 
vitro. For the series of Q3G derivatives, the ACE assay has resulted in significantly stronger 
ACE  inhibitory  potential  for  the  parent  compound  Q3G  than  its  lipophilized  derivatives 
(p≤0.05). The IC50 value for Q3G was 24.3 µM while the IC50 values for Q3G derivatives ranged 
between 68.0 to 90.9 µM. The EPA (IC50 68.0 µM) and DHA (IC50 70.8 µM) esters of Q3G 
showed  the  strongest  ACE  inhibition  among  all  the  Q3G  derivatives.  Opposite  to  the  renin 
inhibitory analysis, the oleic and α-linoleic esters of isoquercitrin exhibited weak ACE inhibitory 
Concentration 
(μM)
x 
In vitro Percentage inhibition of Angiotensin Converting Enzyme (ACE)
 § 
  Q3G
∞  Q3G-
Stearic 
Q3G-
Oleic 
Q3G- 
Linoleic 
Q3G- α 
Linoleic 
Q3G-
EPA 
Q3G-
DHA 
1  15.07
d  3.42
d  5.60
d  N.D
y  N.D  5.61
d  12.30
d 
10  30.88
c  8.54
c  8.65
c  9.93
c  8.39
c  29.25
c  28.86
c 
100  75.17
b  54.42
b  52.55
b  60.18
b  63.24
b  56.67
b  55.68
b 
1000  91.24
a  89.27
a  84.89
a  84.70
a  76.22
a  76.63
a  73.48
a 
IC50
z
 (μM)  24.28
b  72.96
g  84.77
h  73.69
g  90.92
i  68.03
f  70.80
f 
  PZ  PZ-
Stearic 
PZ-Oleic  PZ-
Linoleic 
PZ-α-
Linoleic 
PZ-
EPA 
PZ-DHA 
1  3.04
d  9.54
d  12.52d  8.54
c  5.46
c  7.62
c  9.98
c 
10  9.57
c  16.50
c  23.78
c  38.86
b  34.57
b  49.30
b  27.93
b 
100  43.20
b  61.89
b  71.07
b  79.91
a  86.14
a  87.08
a  81.24
a 
1000  80.57
a  85.71
a  85.06
a  80.24
a  88.40
a  89.35
a  86.23
a 
IC50 (μM)  123.96
j  54.59
e  37.27
d  26.57
c  23.91
b  16.03
a  28.21
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potential (p≤0.05). The weakest ACE inhibitor in vitro in Q3G series was its α-linoleic ester with 
IC50 value of 90.9 µM (p≤0.05). The ACE inhibitory activity of phloridzin and its derivatives 
followed its trend of renin inhibitory analysis. All of the phloridzin series esters showed the 
stronger  antihypertensive  potential  (p≤0.05)  than  their  parent  compound  phloridzin,  which 
represented the weakest ACE inhibition with IC50 value of 123.9 µM (p≤0.05). The IC50 values 
of phloridzin esters ranged between 16.03 and 54.6
 µM. The strongest ACE inhibitory potential 
among the compounds was that of EPA ester of phloridzin (IC50 16.03 µM) with approximately 
eight times lower IC50 value than phloridzin. It was closely followed by its α-linolenic acid ester 
(IC50 23.9 µM) as strong ACE inhibitor (p≤0.05). Unlike ACE inhibition by oleic and α-linoleic 
esters of isoquercitrin, their phloridzin counterparts were potent ACE inhibitors (p≤0.05). The 
weakest ACE inhibition in phloridzin series esters was exhibited by its stearic acid ester (IC50 
54.59 µM) with approximately two times weaker ACE inhibition than phloridzin. Overall, the 
long chain EPA and docosahexaenoic acid (DHA) esters of phloridzin emerged as the potent 
ACE inhibitors in vitro. 
 
Aldosterone synthase inhibition: Aldosterone, produced by aldosterone synthase, is a principal 
mineralocorticoid in humans that plays a part in fluid regulation and hypertension. The blockage 
of  its  mineralocorticoid  receptor  is  accompanied  by  the  alternative  approach  of  aldosterone 
synthase inhibition  for treating hypertension  [19].  Polyphenols  have been found to  attenuate 
hypertension and its pathological manifestations in rodent model of hyperaldosteronism [20]. 
Our study was focused on possible aldosterone synthase inhibition by two flavonoids and their 
derivatives in vitro (Figure 1).  
 
 
Figure 1. Aldosterone synthase inhibition by novel fatty acid esters of Isoquercitrin (Q3G) and 
Phloridzin (PZ) in vitro. Data are presented as percentage inhibition. Phloridzin (PZ); Stearic acid ester of PZ 
(PZ-Steric); Oleic acid ester of PZ (PZ- Oleic); Linoleic acid ester of PZ (PZ- Lino); α-linolenic acid ester of PZ 
(PZ-  alpha);  Eicosapentaenoic  acid  ester  of  PZ  (PZ-EPA);  Docosahexaenoic  acid  ester  of  PZ  (PZ-DHA); 
Isoquercitrin (Q3G); Stearic acid ester of Q3G (Q3G-Steric); Oleic acid ester of Q3G (Q3G- Oleic); Linoleic acid 
ester of Q3G (Q3G- Lino); α-linolenic acid ester of Q3G (Q3G- alpha); Eicosapentaenoic acid ester of Q3G (Q3G-
EPA). Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 215 of 221 
The results showed very weak inhibition of aldosterone synthase by assayed compounds. 
The overall inhibition percentage of aldosterone synthase by assayed compounds ranged from 
5.03%  to  11.98%.  In  the  Q3G  series,  some  of  the  fatty  acid  derivatives  exhibited  higher 
aldosterone synthase inhibition, compared to the parent compound (Q3G). Q3G displayed 8.3% 
inhibition of aldosterone synthase in vitro. The highest amount of inhibition was shown by oleic 
acid ester of Q3G (12.0%) while its stearic acid ester exhibited the lowest inhibition (5.3%) at 
100 µM. The phloridzin series also exhibited very weak inhibition of the enzyme as the parent 
compound  exhibited  only  5.0%  inhibition  while  its  stearic  acid  derivative  showed  11.3% 
inhibition in vitro. However, there was no significant difference among the Q3G and phloridzin 
series compounds assessed (p≤0.05) for their aldosterone synthase inhibition. 
 
Correlation  Analysis:  Correlation  analysis  was  conducted  to  see  the  interrelation  between 
selected biological profiles  (ACE and renin  inhibition) of the flavonoids  and their structural 
derivatives (Table 3). The Pearson coefficient was obtained using Minitab 16 (State College PA, 
USA). Among the Q3G series, there was a strong direct relationship between ACE and renin 
inhibition in stearic acid, EPA and DHA esters. The parent compound Q3G exhibited a strong 
inverse relationship between ACE and renin inhibition in vitro. However, due to small sample 
sizes (n=3) the Pearson coefficient obtained from Q3G series was not statistically significant 
(p≤0.05).  Similar  to  Q3G  series,  EPA  and  stearic  acid  showed  a  strong  direct  relationship 
between ACE and renin inhibition. Similarly, strong inverse relationship was also seen in second 
parent compound, phloridzin.  
 
 Table 3 Correlation between extent of ACE and renin inhibition. 
 
Compound 
no.  Compound 
ACE Inhibition 
(IC50
∞ value) 
Renin Inhibition 
(IC50 value) 
Pearson 
correlation 
 
p-value 
1  Phloridzin (PZ)  123.96  >200  -0.961  0.124  
2  Stearic acid ester of PZ  54.59  76.45  0.673  0.530 
3  Oleic acid ester of PZ  37.27  72.89  0.314  0.739 
4  Linoleic acid ester of PZ  23.91  70.86  0.346  0.779 
5  α-Linolenic acid ester of PZ  26.57  69.94  0.571  0.439 
6  EPA ester of PZ  16.03  79.19  0.789  0.342 
7  DHA ester of PZ  28.21  95.61  -0.535  0.641 
8  Isoquercitrin (Q3G)  24.28  >200  -0.725  0.215 
9  Stearic acid ester of Q3G  72.96  89.34  0.836  0.370 
10  Oleic acid ester of Q3G  84.77  73.03  -0.142  0.909 
11  Linoleic acid ester of Q3G  90.92  76.37  0.693  0.513 
12  α-Linolenic acid ester of Q3G  73.69  78.69  -0.019  0.988 
13  EPA ester of Q3G  68.03  93.09  0.765  0.446 
14  DHA ester of Q3G  70.80  81.49  0.815  0.619 
 
∞Inhibitory Concentration 50 percent (IC50) 
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The common feature of both series was a strong inverse relationship between ACE and renin 
inhibition by parent flavonoids, along with a direct relationship between EPA and stearic acid 
esters of parent compounds. 
 
DISCUSSION: 
The current study was conducted to investigate and compare the antihypertensive activity of 
flavonoids  and  their  derivatives  in  vitro.  The  enzyme  inhibition  assays  were  conducted  to 
examine the RAAS inhibitory potential of two flavonoids and their derivatives. The isoquercitrin 
emerged as a weak inhibitor of renin in vitro like other large polyphenol molecules, including    
(-)-epigallocatechin  gallate (IC50 = 45 µM), (-)-epicatechin  gallate (IC50 = 619 µM) and (-)-
epigallocatechin  (IC50  =  2175  µM)  [21].  We  found  that  in  Q3G  series  of  compounds,  the 
strongest  renin  inhibitory  potential  was  exhibited  by  oleic  acid  ester  of  Q3G.  Oleic  acid,  a 
monounsaturated omega-9 fatty acid has diverse biological properties including antihypertensive 
activity. A previously reported rodent model study
 [22] also confirmed improved renin inhibition 
using emulsion formulation containing oleic acid. Similarly, another study also confirmed the 
strong renin inhibitory properties of oleic acid [23]. The renin inhibitory activity of Q3G series 
shows  that  enzymatic  esterification  significantly  improved  the  renin  inhibition  in  vitro.  The 
presence of double bonds  in  fatty acids  of the Q3G derivatives may  be associated with  the 
improved enzyme inhibition.  Although phloridzin in  current  study  emerged  as a  weak renin 
inhibitor but its linoleic (18:2 ɷ-6) and α-linolenic acid (18:3 ɷ-3) esters emerged as most potent 
renin inhibitors in vitro. The results from the current study are similar to earlier investigations 
[23,  24]  confirming  the  independent  renin  inhibition  by  linoleic  acid.  Earlier  reports  also 
suggested  that  linoleic  acid  modulates  renin  in  vivo  [24].  The  linoleic  acid  derivative  of 
phloridzin holds strong clinical relevance as linoleic acid also exhibits strong renin inhibition in 
human plasma [25]. While a large body of scientific data confirms independent renin inhibitory 
activity of linoleic acid [23-25]
 but there is no literature that provides strong support for the 
current results, showing α-linolenic acid ester as renin inhibitor. When compared to a clinical 
renin  inhibitor,  aliskiren (IC50  0.6  nM),  with  bioavailability  2.6%  [26]  these  esterified 
compounds may exhibit higher bioavailability leading to renin inhibition in vivo. Overall, the 
IC50 values indicated a common feature in both series of compounds, i.e., the stronger renin 
inhibitory potential of esterified flavonoids. Based on the current results, it can be concluded that 
esterification of flavonoids improved their renin inhibitory potential. These results encourage the 
use  of  these  novel  compounds  as  nutraceuticals  or  supplements  for  possible  direct  renin 
inhibition.
 
ACE is responsible for conversion of Angiotensin I (Asp-Arg-Val-Tyr-IIe-His-Pro-Phe-His-
Leu) to Angiotensin II (Asp-Arg-Val-Tyr-IIe-His-Pro-Phe) and this conversion step in RAAS 
pathway serves as a drug target for antihypertensive therapy. An in vitro assay aimed at ACE 
inhibition was conducted in order  to assess the antihypertensive action of flavonoids and their 
esterified  derivatives.  In  Q3G  series,  the  parent  compound  emerged  as  the  strongest  ACE 
inhibitor in vitro compared to its derivatives. However, the EPA (20:5 ɷ-3) and DHA (20:6 ɷ-3) 
esters of Q3G were the most active ACE inhibitors among Q3G series derivatives. An earlier 
report [27] also supported the antihypertensive role of polyunsaturated fatty acids (PUFA), i.e., Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 217 of 221 
EPA and DHA. The increasing number of double bonds in derivatives was found to be a related 
factor for stronger ACE inhibition (Figure 2).  
 
Figure 2.  Structures of selected novel in vitro antihypertensive fatty acid esters of Isoquercitrin 
and Phloridzin 
 
However,  the  comparative  analysis  between  Q3G  and  its  derivatives  showed  that  the 
addition of long chain fatty acids to Q3G didn’t exhibit an impact on the ACE inhibition. The 
loss of the hydroxyl group from sugar moiety could be a contributory factor resulting in lower 
ACE inhibition by Q3G derivatives compared to their parent compound. In the phloridzin ester 
series, the EPA (20:5 ɷ-3) ester emerged as the strongest ACE inhibitor. EPA ester of phloridzin 
with polyene saturation and a higher number of double bonds exhibited a stronger interaction 
with ACE enzyme in vitro. The α-linolenic acid ester (18:3 ɷ-3) of phloridzin closely followed 
the EPA ester of phloridzin in ACE inhibition.  The findings are supported by earlier evidence 
which suggests the nontoxic and strong antihypertensive potential of α-linolenic acid in vivo in 
humans [28]. The weakest ACE inhibitor among phloridzin esters, i.e., stearic acid derivative of 
phloridzin, (IC50 54.6 µM) exhibited approximately two times weaker ACE inhibitory activity 
than the parent compound. The stearic acid (18:0) esters in both series of compounds exhibited 
weak ACE inhibition. The absence of double bonds and saturated status could be a contributory 
 4'''
18'''
1''' 2'''
3''' 5'''
6'''
7'''
8'''
9''' 10'''
11'''
12''' 13'''
14'''
15''' 16'''
17'''
OH
O
OH
O H
O
O
OH
O H
O H
O
O
1
2 4
5
6
1'
2'
3'
4'
5'
6'
1'' 2''
3''
4'' 5'' 6''


                  
α-Linolenic acid Ester of Phloridzin; 18:3 (n-3) 
Molecular Formula = C39H52O11 
Formula Weight = 696.82358 
Composition = C(67.22%) H(7.52%) O(25.26%) 
 
O
OH
O
OH
O H
O
O
OH
O H
O H
O   4'''
18'''
1''' 2'''
3''' 5'''
6'''
7'''
8'''
9''' 10'''
11'''
12''' 13'''
14'''
15'''
16'''
17'''
1
2 4
5
6
1'
2'
3'
4'
5'
6'
1'' 2''
3''
4'' 5'' 6''


 
Linoleic acid Ester of Phloridzin;18:2 (n-9) 
Molecular Formula   = C39H54O11 
Formula Weight = 698.83946 
Composition = C(67.03%) H(7.79%) O(25.18%) 
1
2
3
4 5
6
 4'''
18'''
1'
2'
3'
4'
5'
6'
1'' 2''
3''
4'' 5'' 6''
1'''
2'''
3''' 5'''
6'''
7'''
8'''
9''' 10'''
11'''
12'''
13'''
14'''
15'''
16'''
17'''
7
8
O
O
O
O
O H
OH
OH
O H
O
OH
OH
O
O H
10
9 
 
Oleic Acid Ester of Isoquercitrin;18:1 (n-9) 
Molecular Formula = C39H52O13 
Formula Weight = 728.82238 
Composition = C(64.27%) H(7.19%) O(28.54%) 
 
  4'''
18'''
1''' 2'''
3''' 5''' 6'''
7'''
8''' 9'''
10'''
11''' 12'''
13'''
14''' 15'''
16'''
17'''
OH
O
OH
O H
O
O
OH
O H
O H
O
O
1
2 4
5
6
1'
2'
3'
4'
5'
6'
1'' 2''
3''
4'' 5'' 6''


19''' 
20''' 
 
Eicosapentaenoic Acid Ester Phloridzin; 20:5 (n-3) 
Molecular Formula = C41H52O11 
Formula Weight = 720.84498 
Composition = C(68.31%) H(7.27%) O(24.41%) Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 218 of 221 
factor towards weak ACE inhibition by stearic acid esters of flavonoids. Interestingly, the loss of 
hydroxyl  group  in  phloridzin  esters  did  not  result  in  lower  ACE  inhibitory  potential.  The 
improved ACE inhibitory activity of the phloridzin esters could be due to flexible phloridzin 
backbone, i.e., more conformational isomers resulting in its free rotation [12]. With a higher 
number of conformational isomers, it is possible that phloridzin might interact better with the 
ACE enzyme. The strong ACE inhibitory potential of precursor flavonoids esterified with EPA 
was a common feature of the analysis. The IC50 value of EPA ester of phloridzin was at par with 
active  natural  ACE  inhibitors  including  epicatechin  –  tetramer  (IC50  4  µM),  epicatechin  – 
hexamer (IC50 8 µM), quercetin-3-O-glucuronic acid
 (IC50 27 µM) and captopril (IC50 1 µM) [4]. 
Based on the results, it can be concluded that fatty acid esters of phloridzin are stronger ACE 
inhibitors compared to the Q3G derivatives. The EPA and α-linolenic acid esters of phloridzin 
emerged  as  promising  ACE  inhibitors  in  vitro.  The  results  suggest  that  these  flavonoid 
derivatives can be explored as potential candidates for ACE inhibition in vivo. 
The final assay focused on the aldosterone synthase inhibitory activity of the compounds. 
All compounds exhibited very weak inhibitory activity against aldosterone synthase.  The oleic 
(18:1 ɷ-9), α-linoleic acid (18:3 ɷ-3) and steric acid (18:0) esters of flavonoids exhibited strong 
aldosterone synthase inhibition. Among all of the compounds assayed, the oleic acid (18:1 ɷ-9) 
ester of Q3G was the strongest aldosterone synthase inhibitor. The findings of this study are 
similar to  an  earlier report  [29], which showed that oleic acid  was  most  potent inhibitor of 
aldosterone  synthesis  among  fatty  acids  and  also  inhibited  the  aldosterone  synthesis  from 
exogenous  18-hydroxycorticosterone.  Similarly,  another  study  further  confirmed  aldosterone 
inhibition  by  oleic  acid  [30].  Among  the  phloridzin  series,  all  compounds  exhibited  higher 
aldosterone synthase inhibition than the parent compound, phloridzin. The oleic acid ester of 
phloridzin showed similar activity and almost equal enzyme inhibition compared to the oleic 
acid derivative of Q3G. These results are in accordance with a previous report which suggested 
that fatty acids may regulate aldosterone secretion and mediate blood pressure [31]. However, in 
both Q3G and PZ series, there was no significant difference among all the compounds assessed 
(p≤0.05) for their aldosterone synthase inhibition. The current study revealed that lipase assisted 
esterification  of  flavonoids  significantly  improved  their  antihypertensive  activities  as  they 
emerged as active dual RAAS inhibitors in vitro. 
 
CONCLUSION: 
The fatty acid esters of Q3G and phloridzin were found to be potential antihypertensive agents 
based on the inhibition of renin, ACE and aldosterone synthase in vitro. The novel compounds 
emerged as promising renin inhibitors in vitro as both series of derivatives exhibited stronger 
renin  inhibition  compared to  their parent  compounds.  The linoleic acid  and  α-linolenic acid 
esters of phloridzin were the most potent renin inhibitor amongst all of the compounds assayed, 
thus promising therapeutic attenuation of hypertension. The EPA ester of phloridzin was the 
most effective ACE inhibitor identified among both series of flavonoids and their derivatives. 
Overall,  the  phloridzin  esters  were  stronger  ACE  inhibitors  in  vitro  compared  to  their  Q3G 
counterparts.  Following  the  trend,  all  phloridzin  esters  also  exhibited  stronger  potency  in 
inhibiting  aldosterone  synthesis  compared  to  their  parent  compound.  In  the  series  of  both 
flavonoids  (Q3G  and  PZ),  the  oleic  acid  derivatives  were  strong  inhibitors  of  aldosterone Functional Foods in Health and Disease 2014; 4(5):208-221                                                            Page 219 of 221 
synthase in vitro. The improved biological activity of the phloridzin esters could be related to 
flexible phloridzin backbone and addition of biologically active fatty acids as it increased the 
lipophilicity  of  the  compounds,  which  can  enhance  hydrophobic  interactions  with  enzyme 
targets. The results suggest that novel fatty acid derivatives of flavonoids have strong potential as 
dual RAAS modulators through enzymatic inhibition. However, studies in vivo using animal 
models and clinical studies are required to confirm the in vitro findings.   
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